Penny Sather
Rheumatology · Spokane, WANPI 1184127409
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 208 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 42.6% of the total. 2025 is the largest year on record at $1,591, 5.9 times the $272 reported in 2022.
Across 208 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$1K
- UCB, Inc.$342
- Lilly USA, LLC$304
- Johnson & Johnson$224
- AstraZeneca$109
- plus $530 from 13 others
What the payments were for
- Food & beverage$4,383100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 76 | $1,869 |
| Amgen | 61 | $1,005 |
| UCB, Inc. | 16 | $342 |
| Lilly USA, LLC | 11 | $304 |
| Johnson & Johnson(2 entities) | 12 | $224 |
| AstraZeneca | 4 | $109 |
| GSK | 5 | $107 |
| Pfizer | 6 | $99 |
| Organon | 3 | $63 |
| E.r. Squibb & Sons, L.L.C. | 3 | $44 |
| Actelion Pharmaceuticals US, Inc. | 3 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $32 |
| Boehringer Ingelheim | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Sanofi | 1 | $24 |
| Fresenius Kabi USA, LLC | 1 | $23 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
How this compares
$4,383 in reported general payments places this provider in the 80th percentile of 157 rheumatology providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RinvoqUpadacitinib | 12 | $125,992 |
| Taltz AutoinjectorIxekizumab | 13 | $85,542 |
| KevzaraSarilumab | 12 | $53,420 |
| MethotrexateMethotrexate Sodium | 251 | $6,114 |
| Hydroxychloroquine Sulfate | 89 | $4,168 |
| Leflunomide | 60 | $2,765 |
| Mycophenolate Mofetil | 17 | $1,614 |
| Sulfasalazine DrSulfasalazine | 22 | $1,092 |
| Prednisone | 101 | $707 |
| Azathioprine | 12 | $575 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $481 |
| Folic Acid | 24 | $279 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $183 |
| Cyclobenzaprine Hcl | 17 | $123 |
| Meloxicam | 18 | $13 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq | $1,869 | $125,99212 claims |
| SanofiKevzara | $24 | $53,42012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 157 rheumatology providers in Washington.
Other rheumatology in Spokane
- Howard KenneySpokane$132K
- Eric MuellerSpokane$14K
- Usman AjazSpokane$11K
- Michael CoanSpokane$10K
- Rebecca MunteanSpokane$8K
- Barbara JacobsSpokane$5K
- Jeffrey ButlerSpokane$3K
- Raksha PradhanSpokane$2K
- Sean LasalleSpokane$992
- Lauren JohnsonSpokane$887
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.